You are here

  • Home
  • Archive
  • Volume 53, Issue 10
  • CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial

Citation Tools

Article menu
Download PDFPDF
Inflammatory bowel disease
CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Sandborn WJ, Feagan BG, Radford-Smith G, et al
CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial
Gut 2004;53:1485-1493.